Posts

NutraLife Biosciences, Inc. Enters Into Joint Venture with Henning Trading LLC to Cultivate and Process Hemp for 2019 U.S. Grow Season

Coconut Creek, FL – (NewMediaWire) – April 11, 2019 –  NutraLife Biosciences, Inc. (the “Company” or “NutraLife”) (OTCQB: NLBS) announces that its wholly-owned subsidiary, PhytoChem Technologies, Inc. (“PhytoChem”) has entered into a joint venture with Henning Trading LLC (“Henning Trading”). NutraLife and Henning plan to cultivate, harvest and process hemp initially in Wisconsin for the 2019 grow season. NutraLife recently announced that it had received licenses from the state of Wisconsin to grow and process hemp.

 

NutraLife’s joint venture with Henning Trading will be under the direction of NutraLife’s Chief Executive Officer and President, Edgar Ward, and Henning’s President, John Henning Jr., its Chief Operating Officer, Adam Bilbrey, its Chairman, John Bilbrey and its sales director, Michael Ward.  Henning and PhytoChem plan to pursue opportunities for the cultivation, harvesting, processing and distribution of high-quality bulk and raw bulk material supply of Phytocannabinoid CBD rich hemp finished goods. In addition, NutraLife and Henning Trading will explore participation in the hemp seed propagation, fiber and grain markets.

 

“We are pleased to have finalized our agreement with Henning Trading and look forward to working with John Henning and Adam Bilbrey to pursue the Company’s vertical positioning within the hemp industry. We look forward to continued growth and new opportunities in the Nutraceutical, Hemp and Life Sciences markets as we enter the second quarter of 2019,” said Edgar Ward, CEO and Founder of NutraLife.

 

About NutraLife BioSciences

NutraLife was founded by Edgar Ward in 2010 as NutraFuels, Inc. and since that time he has served as its Chief Executive Officer, President and Director. Under Mr. Ward’s direction, NutraLife’s revenues increased from $225,000 in 2016 to more than $3.7 million in 2018. NutraLife’s Coconut Creek manufacturing facility has been registered with the Food and Drug Administration and its manufacturing facility has operated in accordance with the Good Manufacturing Processes Standard (GMP) for more than five years. NutraLife’s products are tested by its in-house laboratory chemists for strength, purity and contaminants such as heavy metals, pesticides, and solvents. NutraLife offers thirteen different core formulations which it modifies to meet the specifications of its private label customers. NutraLife provides approximately 50 different variations of its core formulations. NutraLife’s private label products include CBD infused oral sprays, tinctures, pet drops, pain balms, face creams, and nutraceutical oral spray products for sleep support and weight loss packaged under the customer’s brand names.

 

About Henning Trading LLC

Henning Trading LLC (“Henning Trading” or “Henning”) was founded in 2018 by John Henning Jr., Adam Bilbrey, and Henning’s Chairman, J.P. Bilbrey. J.P. recently retired as Chairman, CEO and President of The Hershey Company (HSY).  Henning was founded to provide logistics, sourcing and extraction production for industrial hemp.

 

John Henning, Jr. is a graduate from the University of Mississippi with a Bachelor of Science.  John owns and operates Henning farm in Kingman, Kansas that has been in the Henning family for 4 generations. Using the experience and knowledge he gained from his family’s farming operations, John entered the industrial hemp market focusing on growing methods and cultivation and is considered a master grower.

 

Adam Bilbrey is a co-founder and President of Rental Geek, Inc, a company that revolutionized the off-campus student real estate rental market. Adam is also a co-founder and active officer at Famous Vape, Inc and a co-founder and majority partner at iMed Delivered, Inc.  Adam holds a Master’s in Business Administration and Bachelor of Science in Business from Kansas State University.

 

Mr. John P. Bilbrey, also known as J.P. serves as Member of Board of Directors at Elanco Animal Health Incorporated since March 13, 2019. He was Non-Executive Chairman of The Hershey Company since April 2, 2015 until May 02, 2018. Mr. Bilbrey served as the Chief Executive Officer and President of The Hershey Company from May 17, 2011 to March 1, 2017. Mr. Bilbrey served as the Chief Operating Officer and Executive Vice President of The Hershey Company from November 2, 2010 to May 17, 2011. He served as the President of North America at The Hershey Company from December 2007 to November 2010 and served as its Senior Vice President from November 2005 to November 2010. Mr. Bilbrey has more than 20 years of international consumer sales and marketing experience at Procter & Gamble, which included several overseas assignments. He served as the President of International Commercial group from November 2005 to December 2007 and Senior Vice President of Hershey International from 2003 to December 2007 at The Hershey Company. Mr. Bilbrey served as an Executive Vice President of Sales of Mission Foods since 2003; and served as the President, Chief Executive Officer and Executive Vice President of Retail Sales of Danone Waters of North America, Inc., a division of Groupe Danone, Paris since 2001; Owner and Operator of Commercial Cattle Operations of Bilbrey Farms and Ranch since 1999 and Director of Corporate Sales, Taiwan – Procter & Gamble Company since 1998. He served as an Independent Director of McCormick & Company, Incorporated from November 2005 to May 27, 2015. Mr. Bilbrey has been an Independent Director at Colgate-Palmolive Company since March 13, 2015. He was a Director of The Hershey Company since June 2011 until May 02, 2018. He holds a Bachelor’s Degree in Psychology from Kansas State University.

 

Forward-Looking Statements

This press release contains statements of a forward-looking nature about NutraLife BioSciences, Inc. (“NutraLife” or the “Company”) and Henning Trading, LLC. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect the Company’s financial condition, results of operations, business strategy and financial needs. There is no assurance that the Company’s current expectations and projections are accurate or that the Company’s plans to cultivate, harvest and process Hemp with Henning Trading will be successful. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the Section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission on April 2, 2019. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on the Company’s business or the extent to which any factor, or combination of factors may cause actual results to differ from those contained in any forward-looking statements. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applies.

NutraLife Biosciences, Inc. (OTCQB: NLBS) Provides Shareholder Update

NutraLife Biosciences, Inc. (the “Company” or “NutraLife”) (OTCQB: NLBS) is pleased to announce revenue growth of approximately 107.3% in 2018, the filing of its revenue growth of approximately 107.3% in 2018, the filing of its Annual Report on Form 10-K and audited financial results. Highlights from the Company’s financial results reported in its Form 10-K for the year ended December 31, 2018 include:

  • Sales increased to $3,711,327 for the year ended December 31, 2018 compared to $1,790,168 for the year ended December 31, 2017, an increase of approximately 107.3%.
  • Cost of sales was $2,211,039 compared to $1,055,042 for the years ended December 31, 2018 and 2017, respectively, or a 109.6% increase.
  • Net Loss decreased approximately 91.3% to $2,074,537 in the year ended December 31, 2018 from $23,629,117 in 2017.
  • Gross margin for the year ended December 31, 2018 was $1,500,288, a 104.1% increase over the year ended December 31, 2017.
  • Sales of CBD products increased from approximately $1,380,000 for the year ended December 31, 2017 to $2,400,000 for the year ended December 31, 2018 representing 77% and 78% of our revenues for such periods.

“We are pleased to announce our audited financial statements with improved quarter-to-quarter and annual growth as our revenue grew to $3,711,327 for the year ended December 31, 2018, an increase of approximately 107.3% over 2017. We look forward to continued growth and new opportunities in the Nutraceutical, CBD and Life Sciences markets as we enter the second quarter of 2019.,” said Edgar Ward, CEO and Founder of NutraLife.

2018 Operational Overview

NutraLife’s manufacturing facility has been registered with the Food and Drug Administration and its manufacturing facility has operated in accordance with the Good Manufacturing Processes Standard (GMP) for more than five years. The Company’s products are tested by its in-house laboratory chemists for strength, purity and contaminants such as heavy metals, pesticides, and solvents. The Company offers thirteen (13) different core formulations which it modifies to meet the specifications of its private label customers. NutraLife BioSciences provides approximately 50 different variations of its core formulations. The Company’s private label products include CBD-infused oral sprays, tinctures, pet drops, pain balms, and face creams, and nutraceutical oral spray products for sleep support and weight loss packaged under the customer’s brand names.

New Facility

In April 2017, the Company secured a 20,000 square foot manufacturing facility, which is being custom built to accommodate high-speed high capacity manufacturing of the Company’s products. The Company expects the build-out to be complete and production to begin this summer. The facility will provide more than 9,000 square feet of manufacturing with a total of 17,000 square feet of processing space to meet the increased demand for the Company’s products and services.

Subsidiaries

The Company recently established its wholly owned subsidiaries which are now engaged in operations:

  • Precision Analytic Testing, LLC, a Florida limited liability company (“PAT”) formed on May 11, 2017
  • NutraDerma Technologies, Inc, (“NutraDerma”) a Florida corporation formed on January 28, 2019
  • PhytoChem Technologies, Inc., a Florida corporation (“PhytoChem”) formed on February 4, 2019

Recent Developments

In November of 2018, PAT began providing bulk material analytical, identity, potency and purity testing of raw industrial hemp.

In December of 2018, the U.S. Food and Drug Administration completed an evaluation of three generally recognized as safe (GRAS) notices for hemp seed derived food ingredients. The FDA stated that hulled hemp seed (GRN765), hemp seed protein powder (GRN771), and hemp seed oil (GRN778) are GRAS under their intended conditions of use. Our CBD products are made from seeds and mature stalks of hemp and contain only trace amounts of THC, we believe they qualify as GRAS products.

In January of 2019, NutraDerma acquired the patent for a natural dermal skin patch that is designed to prevent mosquito and other insect bites.  We recently secured manufacturing through a third party and we expect to launch the product in time for the 2019 mosquito season. We have secured production and are in the process of conducting a research study for efficacy. We are also exploring international distribution of the product.

In April of 2019, the Company completed development of its PCR Derma Patch. The PCR Derma Patch delivers 40 mg of Phytocannabinoid rich hemp extract that can last up to four days.

In March of 2019, the Company licensed its technology for a unique system for pharmaceutical grade delivery of testosterone into the human body to a licensed pharmacist, Orlando Pharmacy. The Company expects the first pharmaceutical products using its technology to be available within 30 days.

In March of 2019, we received two licenses from the Wisconsin Department of Agriculture to grow and process industrial hemp within the state. The Company plans to develop efficient, cost reducing growing systems and techniques along with processing technologies for industrial hemp and other botanicals.

In January, the Company completed development of its branded Micro Twist Shots. The products will be sold under the Company’s NutraHempCBD brand. The Company plans to launch the products before the end of April 2019. Micro Twist Shots provide a single dose of the Company’s 5 signature daily health and wellness formulations that include CBD.

Future Strategy

We intend to grow our business by pursuing the following strategies:

  • We plan to continue to brand ourselves as a High-Quality GMP Compliant manufacturer of industrial hemp derived CBD products. Many manufacturers of CBD based products do not operate in compliance with GMP standards. All of our CBD products are tested at multiple stages of the production process to ensure product quality and a THC content of less than 0.3%.
  • We will seek to increase sales to our existing customers by offering additional products. Certain customers of ours began their relationship with us by purchasing only one of our products. Since these initial purchases, we have been able to expand our sales to such customers by offering multiple newly developed high-quality effective products. This strategy has enabled us to expand our product lines and sales to our new and existing customers. Our range of products enables us to pursue many cross-selling opportunities.
  • We seek to increase sales to customers by offering products in categories outside of our traditional product offerings. For example, in November of 2018, through our wholly owned subsidiary PAT, we began providing bulk material analytical, identity, potency and purity testing of raw hemp. In the first quarter of 2019, we took the first steps to commercialize a patented all natural dermal skin patch that prevents mosquito and other insect bites. Through our wholly owned subsidiary PhytoChem, we plan to provide hemp cultivation and raw bulk material extraction and processing starting with our licenses in the state of Wisconsin.
  • We plan to leverage our sales, reputation for quality all natural products to expand our customer base to other private label customers within the life sciences, CBD and Nutraceutical markets.

The financial information contained in this press release is qualified in its entirety by the audited financial statements and financial statement notes included in the Company’s Form 10-K for the year ended December 31, 2018, filed with the Securities & Exchange Commission on April 2, 2019.

Forward-Looking Statements

This press release contains statements of a forward-looking nature. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. NutraLife BioSciences, Inc. (“NLBS” or the “Company”) has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the Section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission on April 2, 2019. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statements. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

Contact:

NutraLife BioSciences, Inc.

6601 Lyons Road, Suite L-6

Coconut Creek, FL  33073

Telephone 888-509-8901

www.NutraLifeBioSciences.com

NutraLife Bioscience, Inc. Receives License to Grow and Process Industrial Hemp

Summary: NutraLife Biosciences, Inc. Receives License to Grow and Process Industrial Hemp in  the state of Wisconsin.

NutraLife Biosciences, Inc. (“the Company” or “NutraLife”) (OTCQB: NLBS) has received two licenses from the Wisconsin Department of Agriculture to grow and process industrial hemp within the state. The Company plans to develop  efficient, cost reducing growing systems and processing technologies for industrial hemp.

Edgar Ward, Founder and CEO of NutraLife commented: “As a company entering the bio life sciences space it is our goal to become vertically integrated as a trusted supplier of raw bulk materials and insure the efficacy and quality of the products produced.”

According to a recent Hemp Industry Daily report, Wisconsin was deemed a ‘new and emerging market’ for hemp and hemp production. The report also names Wisconsin the ‘fastest-moving state yet to allow hemp industry to take root.’ Other up and coming states include California and Virginia, to name a few.

The Company’s in-house products include the NutraHempCBD and NutraSpray brands. The Company manufactures 100% of its in-house products at its FDA approved facility in accordance with GMP.  The Company developed its first branded products in 2013. The Company’s product development, testing and research is conducted by four chemists under the supervision of Mr. Ward.

NutraLife Biosciences, Inc., formerly known as NutraFuels, Inc., (“NutraLife” or the “Company”) also recently announced a name change to NutraLife BioSciences, Inc. and new stock trading symbol, NLBS. The Company believes that the name, NutraLife BioSciences better reflects its current and planned future operations.

The Company is a fully reporting company with a class of securities registered with the U.S. Securities and Exchange Commission (“SEC”). The Company recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. NTFU’s filings with the SEC can be viewed at www.sec.gov. NTFU’s CBD products and information about the company’s direct sales program can be found online at www.nutrahempcbd.com and by following the company on Instagram.

 

* These statements have not been evaluated by the Food and Drug Administration.

* This product is not intended to diagnose, treat, cure or prevent any disease.

 

Forward-Looking Statements

This communication contains statements of a forward-looking nature about NutraLife BioSciences, Inc., (the “Company”). These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission on April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

NutraFuels, Inc., to Change its Name to NutraLife BioSciences, Inc. and Proposed Symbol to NLBS

To read this press release on OTCMarkets.com visit:

NutraFuels, Inc., to Change its Name to NutraLife BioSciences, Inc. and Proposed Symbol to NLBS

Coconut Creek, FL, March 05, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — NutraFuels, Inc. (the “Company”) is pleased to announce a name change to NutraLife  BioSciences, Inc. and a new stock trading symbol, NLBS.  The Company believes that the name, NutraLife BioSciences better reflects its current and planned future operations. Commencing March 6, 2019, the Company’s common shares will trade with the stock ticker symbol “NLBS”.

The Company is a fully reporting company with a class of securities registered with the U.S. Securities and Exchange Commission (“SEC”). The Company recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. NTFU’s filings with the SEC can be viewed at www.sec.gov. NTFU’s CBD products and information about the company’s direct sales program can be found online at www.nutrahempcbd.com and by following the company on Instagram.

* These statements have not been evaluated by the Food and Drug Administration.

* This product is not intended to diagnose, treat, cure or prevent any disease.

Forward-Looking Statements

This communication contains statements of a forward-looking nature. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission on April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

NutraFuels, Inc. fka NutraLife Biosciences, Inc. Explores New Delivery Systems with Pharmaceutical GMP Manufacturer

To read this press release on OTCMarkets.com visit:

NutraFuels, Inc. fka NutraLife Biosciences, Inc. Explores New Delivery Systems with Pharmaceutical GMP Manufacturer

Coconut Creek, FL, Feb. 28, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — NutraFuels, Inc., fka NutraLife Biosciences, Inc. (“the Company” or “NutraFuels”) (OTCQB: NTFU) plans to explore additional options for delivery systems for its nutraceutical and wellness products and pharmaceutical delivery systems.

“We are excited to be exploring our capabilities in the life sciences space by engaging in the research and development of more formulations and enhanced delivery systems with an experienced cGMP pharmaceutical manufacturer,” said Edgar Ward, CEO and Founder of NutraFuels.

The Company plans to explore these various pharmaceutical formulations and delivery systems while utilizing the valuable experience of a cGMP pharmaceutical manufacturer.

The Company manufactures and distributes private label and its own branded products under its NutraHempCBD and NutraSpray brands. The Company’s product development, testing and research are conducted by four chemists under the supervision of Mr. Ward. The Company manufactures 100% of its products at its FDA registered facility in accordance with GMP standards.

The Company is a fully reporting company with a class of securities registered with the U.S. Securities and Exchange Commission (“SEC”). As reported in its Form 8-K filed with the SEC on November 13, 2018, the Company recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. The Company’s filings with the SEC can be viewed at www.sec.gov. NTFU’s CBD products and information about the company’s direct sales program can be found online at www.nutrahempcbd.com and by following the company on Instagram.

* These statements have not been evaluated by the Food and Drug Administration.

* This product is not intended to diagnose, treat, cure or prevent any disease.

Forward-Looking Statements

This communication contains statements of a forward-looking nature about NutraFuels, Inc. (the “Company”). These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission on April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

NutraFuels, Inc. Tests Confirm High Quality Proprietary Ultra Shear Technology Platform

To read this press release on OTCMarkets.com visit:

NutraFuels, Inc. Tests Confirm High Quality Proprietary Ultra Shear Technology Platform

Coconut Creek FL, Feb. 22, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — NutraFuels, Inc. fka NutraLife BioSciences, Inc. (OTCQB: NTFU) (NTFU) and Pressure BioSciences, Inc. (OTCQB: PBIO) (PBI) (together, the “Companies”), in a joint venture, today announce that analytical tests on Hemp-derived CBD oil processed by PBI’s Ultra Shear Technology™ (UST) platform confirm that: (i) UST processing results in the development of a true CBD oil nanoemulsion, and (ii) CBD is neither lost nor modified during the UST process (> 99% recovery).

The proprietary UST platform combines ultra-high pressure with extreme shearing forces to create very small, nano-scale mixtures of fluids that otherwise do not mix, resulting in a highly stable homogenized solution called nanoemulsions.

Dr. Vera Gross, Senior Scientist R&D at PBI, commented: “To determine if the UST process resulted in a loss or modification of CBD during processing, we enlisted the help of our collaborator NutraFuels, Inc. NTFU has an FDA-inspected, highly-qualified analytical laboratory with state-of-the-art equipment and well-trained chemists with years of experience in laboratory testing.”

For many oil-based nutritional and therapeutic products, such as CBD-infused nutraceuticals, nanoemulsions offer superior water solubility and increased bioavailability for improved absorption. Consequently, there is a significant need to develop reliable, scalable methods to process CBD oil into high-quality nanoemulsions, with minimal loss of CBD during the process.

Mr. Cooper Dodd, an R&D Scientist at NTFU, said: “Using a powerful laboratory method called HPLC to measure the concentrations of CBD and potential impurities, we determined that no appreciable amount of CBD was lost during the UST process. These results compare well to our standard processing method of ultrasonication, which can carry a risk of measurable loss of CBD, and sometimes create the appearance of impurities if not performed properly. While there is more work to be done, as a nutraceutical manufacturer with products already on the market, we see these results as a robust leap towards better optimization of our CBD-enhanced products.”

Dr. Gross, Director of Applications Development from PBI, added: “To determine if UST processing of CBD oil generates true nanoemulsions, we asked an independent, university-affiliated laboratory to determine the size of oil droplets in post-UST processed material using a universally-accepted sizing method called DLS. Their results showed that post-UST processed oil droplets were approximately 65 nm in size, well within the range of 20-200 nm generally accepted as defining a true nanoemulsion (Nano- and Microscale Drug Delivery Systems, 2017).”

Professor Keith Warriner, Professor of Food Science at the University of Guelph, and a recognized expert in the cannabis industry, commented: “The data disclosed today on UST-generated nanoemulsions of CBD oil are very impressive. Creating nanoemulsions of CBD oil with full preservation of CBD throughout the process, while not generating impurities, remains a significant challenge in the industry. These data offer great promise to the future.”

Professor Warriner continued: “Although there is great excitement over CBD-infused edibles and beverages, and rightfully so, I believe that CBD-infused topicals may be an even greater market for CBD products in the near future. However, to be successful, it is imperative that topicals be highly stable, bioavailable and readily absorbent nanoemulsions. After a review of the data released today, the UST process appears to be a leading candidate to fill that need.”

Dr. Bradford A. Young, Chief Commercial Officer of PBI, commented: “We were very excited to share the news just last week of PBI’s visually obvious successful production of water-soluble CBD Oil. However, the addition of these scientific validations of our successful achievement of creating nanoemulsions by the UST platform, and our preservation of CBD levels all the way through to the finished product are frankly the crowning touch to the news of these accomplishments.  We believe our proprietary Ultra Shear Technology will be a pivotal change agent strongly affecting the future of many major existing product areas, spanning foods, nutraceuticals, therapeutics, cosmetics, lubricants, paints, and other industries.”

About NutraFuels, Inc.

NutraFuels, Inc. fka NutraLife BioSciences, Inc. was founded in 2010 and has evolved into a branded and private label developer, distributor and Food and Drug Administration registered (FDA) manufacturer. NTFU’s products include a range of nutraceutical, wellness, and CBD products as well as a cosmetics line. NutraFuels’ manufacturing process received the Good Manufacturing Processes Standard (GMP) certification. Its products adhere to high manufacturing standards throughout every step of the manufacturing and extraction process. NTFU’s product testing and research and development are conducted by four chemists under the direction of NTFU’s founder and Chief Executive Officer, Edgar Ward.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO ’s primary focus is in the development of high pressure-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, food science, soil & plant biology, forensics, and counter-bioterror applications. Additionally, PBIO is actively expanding the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired protein disaggregation and refolding technology from BaroFold, Inc. to allow entry into the biologics manufacturing and contract research services sector, and (2) the use of its recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward-Looking Statements

This press release contains forward-looking statements about NutraFuels, Inc. and Pressure BioSciences, Inc. (collectively the “Companies”). These statements relate to future events or the Companies’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause each of the Companies industry results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. These forward-looking statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Companies have based these forward-looking statements largely on their current expectations and projections about future events and financial trends that the Company believes may affect their respective financial condition, results of operations, business strategy, and financial needs. These statements are only predictions based on each of the Companies current expectations and projections about future events. Investors should not place undue reliance on these statements. In evaluating these statements, Investors should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause the Companies’ actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in each of the Companies’ Annual Reports and other reports filed from time to time with the Securities & Exchange Commission (SEC). More detailed information about these risk factors are set forth in the Companies’ filings with the SEC. The Companies encourage Investors to review these risk factors. The Companies undertake no obligation to update any of the information included in this release, except as otherwise required by law.

NutraFuels, Inc. and Pressure BioSciences, Inc. to Collaborate on the Development of Water-Soluble Nanoemulsion-based NutraceuticalsView Press Release on OTCMarkets.com

Coconut Creek, FL, Jan. 30, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — NutraFuels, Inc. (OTCQB: NTFU) (NTFU) and Pressure BioSciences, Inc. (OTCQB: PBIO) (PBI) (together, the “Companies”) today announced a collaboration to advance the development of a new generation of health and wellness nutraceutical products based on processing by PBI’s proprietary Ultra Shear Technology (UST™) platform. The Companies believe that nanoemulsions prepared by the UST Platform will have improved quality and effectiveness compared to current emulsions, which will help to facilitate the development of a new generation of improved nutraceutical and other emulsion-based products, such as cosmetics.

PBI is a leader in the development and sale of enabling high pressure-based instruments, consumables, and related services for the life sciences industry.  PBI has more than 300 high-pressure instruments installed in over 200 life sciences laboratories worldwide, including in some of the world’s leading academic, government, and biopharmaceutical laboratories.

 NTFU manufactures and distributes nutritional and dietary supplements focusing on in-house product development and the highest manufacturing standards. All quality control testing and manufacturing processes are in compliance with FDA and cGMP standards. NTFU has developed multiple products for the wellness and nutraceutical markets, including formulas to support energy and focus, sleep, stress, joints, and weight loss.

 Edgar J. Ward, President and CEO of NTFU, said: “We pride ourselves in ensuring that we incorporate the highest level of quality possible in our manufactured products. When we heard that PBI was developing their new, proprietary UST processing platform, and learned of its potential to significantly increase the quality and effectiveness of nutraceutical products, we spoke with PBI and offered to help accelerate its commercial introduction. We are thrilled to be working with such experienced scientific leaders and innovators, in a program that we believe can change lives worldwide for the better.”

 Mr. Ward continued: “We believe PBI’s UST platform has the potential to create long-term room temperature stable, water-soluble nanoemulsions of oil-based solutions. Nanoemulsions are known to offer greater stability and bioavailability than the standard macroemulsions used today in nutraceuticals, cosmetics, and other industries.  We are excited to have the opportunity to work with a life science industry leader in the optimization of a process that has the potential to bring higher quality not just to our products, but to nutraceutical products worldwide.”

 Dr. Bradford A. Young, Chief Commercial Officer of PBI, commented: “We are pleased to have the opportunity to work with NTFU’s scientists and manufacturing personnel in the development of new and improved nutraceutical products utilizing our UST platform. This proprietary technology employs ultra-high pressure and extreme shearing forces to create nano-scale emulsions of oil and water with long-term stability. For many oil-based products, the ability to create very small, nanometer-sized oil droplets that can effectively dissolve in water (nanoemulsions) can improve a product’s appearance, sensory and medicinal benefits. There is a large and growing market opportunity for nutraceutical products with proven health and wellness benefits. We believe PBI’s UST platform can help manufacturers accelerate growth and success in this market with higher quality, water-soluble, oil-based products with superior dietary absorption and shelf-life.”

 Mr. Richard T. Schumacher, President and CEO of PBI, added: “We are excited to work with Edgar and his NTFU team in the optimization of our UST platform, which we believe will result in the development of new and beneficial health and wellness products.  The staff at NTFU has years of experience in manufacturing nutraceutical products in a quality environment. They also have access to both raw materials and finished goods, both of which are needed for optimization.  Finally, they have an existing analytical laboratory with state-of-the-art equipment and well-trained chemists who can perform testing on both pre and post-processed materials, which will be invaluable to the optimization process. This collaboration clearly supports both company’s strategic objectives: we look forward to an exciting and mutually beneficial relationship with our colleagues at NutraFuels.”

About Pressure BioSciences, Inc. 

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of high pressure-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, food science, soil & plant biology, forensics, and counter-bioterror applications. Additionally, we are actively expanding the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired protein disaggregation and refolding technology from BaroFold, Inc. to allow entry into the biologics manufacturing and contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (UST) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 About NutraFuels, Inc.

 NutraFuels, Inc was founded in 2010 and has evolved into a branded and private label developer, distributor and Food and Drug Administration registered (FDA) manufacturer. NTFU’s products include a range of nutraceutical, wellness, and CBD products as well as a cosmetics line. NutraFuels’ manufacturing process received the Good Manufacturing Processes Standard (GMP) certification. Its products adhere to high manufacturing standards throughout every step of the manufacturing and extraction process. NTFU’s product testing and research and development is conducted by four chemists under the direction of NTFU’s founder and Chief Executive Officer, Edgar Ward.

Forward-Looking Statements

This press release contains forward-looking statements. These statements relate to future events or the Companies’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause each of the Company’s industry results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. These forward-looking statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Companies have based these forward-looking statements largely on  their current expectations and projections about future events and financial trends that they believe may affect their respective financial condition, results of operations, business strategy, and financial needs. These statements are only predictions based on each of the Companies current expectations and projections about future events. Investors should not place undue reliance on these statements. In evaluating these statements, Investors should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause each of the Company’s actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in each of the Company’s Annual Reports and other reports filed from time to time with the Securities & Exchange Commission (SEC). More detailed information about these risk factors are set forth in the Company’s filings with the SEC. The Companies encourage Investors to review these risk factors. The Companies undertake no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about the Companies and this press release, please click on the following website link: 

www.nutrafuels.com        

Telephone 888-509-8901

http://www.pressurebiosciences.com  

NutraFuels, Inc. and Pressure BioSciences, Inc. to Collaborate on the Development of Water-Soluble Nanoemulsion-based NutraceuticalsView Press Release on OTCMarkets.com

Selling cannabis or hemp on Times Square? Florida company makes marketing history

Check out our news article on FloridaPolitics.com

While CBS still won’t run medical marijuana advertisements during the Super Bowl, a Florida company just ran the first-ever ads for cannabis-based products in Times Square.

NutraFuels, a nutraceutical manufacturing company with a line of hemp-derived CBD products under the brand NutraHempCBD (www.nutrahempcbd.com) was in the first digital billboard cannabis campaign in the famed intersection.

“This ad campaign was our way to celebrate the deregulation of hemp and create awareness of its health and wellness benefits,” said Edgar Ward, president and CEO of NutraFuels.

While companies with hemp and cannabis products in the past have tried to buy ad space in Times Square before, the marketing debuted concurrently with a change in the law.

Until this year, federal law technically classified all parts of the cannabis plant as marijuana, a scheduled narcotic. But the 2018 Farm Bill, as explained by the Billings Institute, differentiated hemp, a part of the plant containing less than 0.3 percent tetrahydrocannabinol. Better known as THC, that’s the stuff that gets people high.

“This campaign was our way of celebrating the Farm Bill and the deregulation of hemp,” said NutraFuels spokeswoman Chloe Sommers.

While the federal government long turned a blind eye to the sale of hemp and CBD oil, which can be sold in all 50 states, major media companies would not accept an advertisement for a product still technically prohibited by law.

It’s much the same reasoning that led CBS to reject an advertisement for Acreage Holdings, which sells medical marijuana, on the grounds the government still considers the sale of the product a crime.

But after the deregulation of hemp and CBD, Honeysuckle Magazine, a lifestyle magazine that regularly writes about the organic products, got approval to run a Times Square billboard campaign.

“It sounded interesting to me, so I jumped on the chance,” said Ronit Pinto, Honeysuckle owner. She offered space to many of advertisers working with her company, and many cannabis-related brands took part, including NutraFuels.

It turns out, the campaign marked the first time anyone sold cannabis-based products like hemp and CBD on a Times Square billboard.

“We started realizing what a great opportunity this involved for a lot of our brand partners, and just kept buying more time,” she said. “It became a huge thing.”

NutraFuels advertised its in-house CBD product NutraHempCBD. The ads provided tremendous exposure for the Coconut Beach-beached company, which employs about 12 people.

The Florida business remains one of the companies that’s continued to participate in the campaign as ad buys stretched into February.

The campaign still faces certain restrictions, Pinto said. There can’t be any pictures of the actual cannabis plant.

Advertisements also can’t show drug paraphernalia as the content must focus on those cannabis products legal under the new farm bill.

But the high-profile advertising could mark the first entry into mainstream marketing for a growing cannabis industry. Maybe the Super Bowl in 2020 will see such products promoted in commercial breaks.

“It’s the right thing to do,” Sommers said. “If you are doing the right thing and doing it by the rules, you should be able to market your product and be seen. CBS is buying into a stigma that’s actually flawed.”

“When it comes to cannabis, until the federal cannabis laws change like the hemp laws were, national media companies will be unlikely to accept their advertising,”  said NutraFuels spokesperson Chloe Sommers. “This positions CBD products well and it looks like it will only get better with time.

“When it comes to cannabis, until the federal cannabis laws change like the hemp laws were, national media companies will be unlikely to accept their advertising. This positions CBD products well and it looks like it will only get better with time.”

Fulfill Your Health Resolutions With NutraFuels NutraHempCBD CBD Lifestyle Kits, Nearly 50% Off

Its a New year, and a new you! Check out NutraHempCBDs new 2019 healthy lifestyle starter kits. The Lifestyle Pack includes; NutraHempCBDs best-selling 600mg CBD tincture, the luxurious CBD Face Cream, a bundle of CBD Sleep Twists, and the popular Stress CBD Oral Spray all for $99.99. Originally priced at $188.75 this deal is almost 50% off.

The Lifestyle Pro Pack has its number one 900mg, the CBD Pain Balm, a bundle of CBD Stress Twists, and is completed with a convenient pocket-sized CBD Energy Spray for the discounted price of $129.99. The original market price for all these products together would be $233.75, this kit is nearly 50% off.

Also, back by popular demand is the NutraHempCBD 75% off discount for its 3-pack of Weight loss CBD oral sprays. The NutraHempCBD Weight Loss spray supports weight and appetite control through its formulation of CBD and Garcinia Cambogia(GC). GC has been shown to support healthy blood sugar control. The CBD and GC formulation can also support weight loss.

Use the recommended dose of 6 sprays 15 minutes before your meal and the CBD and Garcinia Cambogia will help as an appetite suppressant and support blood sugar (glucose) control.

Get healthy in 2019 by adding CBD to your routine. These all-in-one CBD lifestyle kits and the weight loss CBD oral spray bundle specials will help you toward a healthy 2019.

NutraFuels Inc. is a nutraceutical company with a line of CBD-infused products known by its in-house brand, NutraHempCBD. Using premium CBD hemp oil, its formulations are designed to promote overall health and wellness. NutraHempCBD products are intended for daily use with observed health benefits including anti-stress, anti-inflammation, calmness to sleep and stay asleep.

NutraFuels, Inc is a fully reporting company with a class of securities registered with the U.S. Securities & Exchange Commission (SEC). As reported in its Form 8-K filed with the SEC on November 13, 2018, NTFU recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. NTFUs filings with the SEC can be viewed at www.sec.gov. NTFUs CBD products and information about the companys direct sales program can be found online at www.nutrahempcbd.com and by following the company on Instagram.

Forward-Looking Statements

This communication contains statements of a forward-looking nature. These statements are made under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as may, will, except, anticipate, aim, estimate, intend, plan, believe, is/are likely to, future or other similar expressions. The Company has based these forward-looking statements largely on the Companys current expectations and projections about future events and financial trends that the Company believes may affect Companys financial condition, results of operations, business strategy, and financial needs. There is no assurance that Companys current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Companys actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Companys filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled Risk Factors, in the Companys Annual Report on Form 10-K with the Securities and Exchange Commission on April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Companys management to predict all risk factors, nor can the Company assess the impact of all factors on Companys business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

Contact:

NutraFuels, Inc.

6601 Lyons Road, Suite L-6
Coconut Creek, FL 33073

Telephone 888-509-8901
www.NutraFuels.com
www.ShopNutraHempCBD.com

Fulfill Your Health Resolutions With NutraFuels NutraHempCBD CBD Lifestyle Kits, Nearly 50% Off

Legalization of Industrial Hemp Positions NutraFuels for Market Expansion

NutraFuels, Inc. (“NTFU” or the “Company”), a nutraceutical company with its own line of CBD products under the name NutraHempCBD, applauds the passage of the 2018 Farm Bill allowing federally insured banks to legally work with merchants for product processing as well as the removal of barriers for research and industrial hemp production.

NTFU applauds the passage of the 2018 Farm Bill allowing federally insured banks to legally work with merchants for product processing as well as the removal of barriers for research and industrial hemp production.

The hemp industry has been challenged over the years because of banking restrictions. It has caused challenges from the standpoint of merchant product processing for hemp-derived CBD products. It also caused headwinds with respect to many aspects of the companies operating in the hemp public markets, said Edgar Ward, CEO and Founder of NutraFuels.

Brightfield Group estimates the worth of the hemp CBD market to be $22 Billion by 2022, outpacing the rest of the cannabis market combined. Weve been planning and preparing for an increase in CBD product demand in anticipation of the passage of the 2018 Farm Bill, added Ward.

The updated language from the Farm Bill defines hemp in a way that removes it from the Controlled Substances Act. Going forward, hemp will be classified as an agricultural commodity under federal law. Farmers will now benefit from the removal of barriers to obtaining crop insurance. Shareholders and manufacturers will see the removal of restrictions on importing and exporting hemp which contributes to the projected boost of growth for the hemp industry.

The lack of legal clarification and the longtime stigma around hemp has dampened the business opportunity and created concern for the investment community, said Ward. The new law provides clarity and the legal parameters to enable companies like NutraFuels to capitalize on a more efficient operating environment and market expansion.

NutraFuels is a fully reporting company with a class of securities registered with the SEC. The Companys filings can be viewed at www.sec.gov. NTFUs CBD products and information about the companys direct sales program can be found online at www.nutrahempcbd.com and by following the company on Instagram.

Forward Looking Statements
This communication contains statements of a forward-looking nature. These statements are made under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as may, will, except, anticipate, aim, estimate, intend, plan, believe, is/are likely to, future or other similar expressions. The Company has based these forward-looking statements largely on the Companys current expectations and projections about future events and financial trends that the Company believes may affect Companys financial condition, results of operations, business strategy, and financial needs. There is no assurance that Companys current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Companys actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Companys filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled Risk Factors, in the Companys Annual Report on Form 10-K with the Securities and Exchange Commission on April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Companys management to predict all risk factors, nor can the Company assess the impact of all factors on Companys business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

Legalization of Industrial Hemp Positions NutraFuels for Market Expansion